Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 66

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 66
---
,669 Commercial paper142,556 120 (55)142,621 Corporate bonds32,502 25 (5)32,522 U.S. federal agency bonds5,996 8 — 6,004 Yankee bond5,012 13 — 5,025           Total$207,692 $209 $(60)$207,841 At March 31, 2025, there were no investments available for sale that were materially less than their amortized cost.The Company elects to recognize its interest receivable separate from its available-for-sale investments. At March 31, 2025 and December 31, 2024, the interest receivable from its available-for-sale investments recognized in prepaid expenses and other current assets was $0.4 million and $0.5 million, respectively.Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term available-for-sale investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally-insured limits. As of March 31, 2025, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 36%, 21% and 19%. At December 31, 2024, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 34%, 18% and 16%. For additional information regarding the Company’s wholesalers, see Note 2, Summary of Significant Accounting Policies. EXPAREL and ZILRETTA revenues are primarily derived from major wholesalers and specialty distributors that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company’s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of March 31, 2025 and December 31, 2024, there were $0.4 million of allowances for credit losses on the Company’s accounts receivable.

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 24

NOTE 11—STOCKHOLDERS’ EQUITY

Accumulated Other Comprehensive IncomeThe following tables illustrate the changes